NCT03181867 2026-04-22
18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
Clinical Trials
1,415 trialsNCT03436654 2026-04-22
Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT03866382 2026-04-22
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT04530552 2026-04-22
Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate Gland
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04523207 2026-04-21
A Study of Apalutamide (Adjuvant Treatment) and Androgen Deprivation Therapy (ADT) in Participants Who Have Undergone Radical Prostatectomy (RP) for Non-metastatic Prostate Cancer and Who Are at High Risk for Metastases
Janssen Research & Development, LLC
Phase 2 Completed
NCT07047118 2026-04-21
A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Novartis
Phase 2 Active not recruiting
NCT06378866 2026-04-20
DIVINE
Mayo Clinic
Phase 2 Recruiting
NCT00951535 2026-04-17
A Prospective Phase II Dose Escalation Study Using IMRT for High Risk N0 M0 Prostate Cancer. ICORG 08-17
Cancer Trials Ireland
Phase 2 Active not recruiting
NCT05766371 2026-04-17
Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer
University of California, San Francisco
Phase 2 Recruiting
NCT07234981 2026-04-17
PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer
University of Nebraska
Phase 2 Recruiting
NCT07535905 2026-04-17
REVIVE
University Health Network, Toronto
Phase 2 Not yet recruiting
NCT05616650 2026-04-16
Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT06347705 2026-04-16
A Study of 2141-V11 in Combination With Standard Treatments in People With Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT03821792 2026-04-15
Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT06161506 2026-04-15
Surface Electrical Stimulation for Urinary Incontinence in Men Treated for Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT07111507 2026-04-15
A Study of Tarlatamab for People With Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT07237269 2026-04-15
Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer
University of Nebraska
Phase 2 Recruiting
NCT01902680 2026-04-14
CURIEFOCALE
Institut Claudius Regaud
Phase 2 Completed
NCT05828082 2026-04-14
Testing the Effect of M1774 on Hard-to-Treat Refractory SPOP-mutant Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT05960578 2026-04-14
Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study
University of Washington
Phase 2 Active not recruiting
NCT02225704 2026-04-13
Radium-223 in Combination With Enzalutamide
Cancer Trials Ireland
Phase 2 Completed
NCT02465060 2026-04-13
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT02772588 2026-04-13
AASUR in High Risk Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT02893917 2026-04-13
Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT02960022 2026-04-13
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
Astellas Pharma Inc
Phase 2 Recruiting
NCT03869762 2026-04-13
DICE
Cancer Trials Ireland
Phase 2 Terminated
NCT04337580 2026-04-13
FASN
Wake Forest University Health Sciences
Phase 2 Recruiting
NCT04550494 2026-04-13
Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT04842890 2026-04-13
Phase II Study of Pencil Beam Scanning Proton Stereotactic Body Radiation Therapy for Prostate Cancer
The New York Proton Center
Phase 2 Active not recruiting
NCT05691465 2026-04-13
Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT05849298 2026-04-13
PSMACare
Novartis
Phase 2 Active not recruiting
NCT06594926 2026-04-13
WOMBAT
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Phase 2 Recruiting
NCT06610825 2026-04-13
CaRPET
Washington D.C. Veterans Affairs Medical Center
Phase 2 Recruiting
NCT07220720 2026-04-13
POSLUMA® (18F-rhPSMA-7.3) PET-CT for PIRADS 2/3 Lesions
University of Florida
Phase 2 Recruiting
NCT00859781 2026-04-08
177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer
Weill Medical College of Cornell University
Phase 2 Active not recruiting
NCT05053152 2026-04-08
Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study
NRG Oncology
Phase 2 Active not recruiting
NCT06632977 2026-04-07
PREDICT
Alliance for Clinical Trials in Oncology
Phase 2 Recruiting
NCT07515651 2026-04-07
MIDAS-SBRT
University Health Network, Toronto
Phase 2 Not yet recruiting
NCT07516210 2026-04-07
ART-Hypo
Centre hospitalier de l'Université de Montréal (CHUM)
Phase 2 Not yet recruiting
NCT03173924 2026-04-06
18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT03976843 2026-04-06
Prostate Specific Membrane Antigen (PMSA)-Based PET Imaging of High Risk Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT04709276 2026-04-06
CHAMP
Duke University
Phase 2 Active not recruiting
NCT05361798 2026-04-06
A Phase II Study Evaluating T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination With the Immunocytokine PDS01ADC in Localized High and Intermediate Risk Prostate Cancer Treated With Androgen Deprivation Therapy
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT07512076 2026-04-06
A Dose Optimization Study of Enzalutamide in Elderly Patients With Advanced Prostate Cancer
Sunnybrook Health Sciences Centre
Phase 2 Not yet recruiting
NCT05059236 2026-04-02
ARASEC
Bayer
Phase 2 Active not recruiting
NCT07005154 2026-04-02
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
Astellas Pharma Inc
Phase 2 Recruiting
NCT07365423 2026-04-02
TerbinaPro
Swiss Cancer Institute
Phase 2 Recruiting
NCT03419234 2026-04-01
Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT04300855 2026-04-01
Clinical Trial of Green Tea Catechins in Men on Active Surveillance
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Active not recruiting
NCT05114746 2026-04-01
Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer in Japan
Novartis
Phase 2 Active not recruiting